Celltrion Files Petitions for IPR of Three Rituximab Patents
By EsqSocial Corporation 17/03/17
Celltrion has filed three petitions for IPR of Biogen’s patents related to rituximab: IPR2017-01093, challenging U.S. Patent 8,329,172; IPR2017-01094 challenging U.S. Patent 8,557,244; and IPR2017-01095 challenging U.S. Patent 9,296,821. Rituximab...
By: Goodwin